Theranostics:北京生科院在甲状腺乳头状癌预后及诊断的分子标志物研究中取得进展

2018-08-02 佚名 北京生科院

甲状腺乳头状癌是内分泌系统中发病率最高的恶性肿瘤,发病率近三十年内上升了三倍。甲状腺乳头状癌的发生是由基因组和转录组等不同层面的多种分子改变所引起的复杂的生物学过程,为了实现该恶性肿瘤的精准诊断、提高治疗和预后评估的效果,亟需从多组学、不同角度系统鉴定癌组织发生、发展过程中的分子改变。

7月30日,中国科学院北京生命科学研究院孙中生研究团队的最新研究成果,以Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma为题,在线发表在Theranostics上。这是该团队首度解析中国人群甲状腺乳头状癌遗传图谱后,在甲状腺乳头状癌的预后及诊疗研究中取得的又一进展。

甲状腺乳头状癌是内分泌系统中发病率最高的恶性肿瘤,发病率近三十年内上升了三倍。甲状腺乳头状癌的发生是由基因组和转录组等不同层面的多种分子改变所引起的复杂的生物学过程,为了实现该恶性肿瘤的精准诊断、提高治疗和预后评估的效果,亟需从多组学、不同角度系统鉴定癌组织发生、发展过程中的分子改变。

在前期研究中,孙中生研究团队运用自主开发的目标区域捕获测序技术,首次绘制中国人群甲状腺乳头状癌的遗传图谱,揭示中外人群甲状腺乳头状癌遗传图谱的差异,为中国人群甲状腺乳头状癌的分子诊断提供了理论依据。研究中,该团队以腺外侵犯这一与甲状腺乳头状癌预后具有密切关系的临床特征为切入点,通过对来自于两个独立的研究队列的655个甲状腺癌病人的转录组数据进行深度分析,发现与细胞微环境及类固醇激素响应有关的基因与甲状腺乳头状癌的腺外侵犯密切相关,预测到能影响甲状腺乳头状癌腺外侵犯表达特征的两个小分子化合物(6-bromoindirubin-3'-oxime、lovastatin),发现长链非编码RNA能通过调控细胞外基质和细胞黏附来影响甲状腺乳头状癌的发生,鉴定了两个新的长链非编码RNA及八个基因与腺外侵犯及甲状腺乳头状癌病人的无病生存率(disease-free survival)显着相关,并在一些已报道的能潜在应用于甲状腺乳头状癌诊断的基因(SERPINA1、FN1)中发现了新的与癌症发生相关的可变剪切事件,为提高这些基因诊断的灵敏性提供了新的分子证据。

研究揭示了与甲状腺乳头状癌发生及侵袭相关的转录组学特征,为这一高发癌症的分子诊断及预后评估提供了新的分子标志物,为甲状腺癌的药物治疗提供了新策略。

该研究得到了国家重点研发计划、国家自然科学基金等的资助。


甲状腺乳头状癌发生发展的转录组学特征研究概要

原始出处:Huajing Teng1, Fengbiao Mao1, Jialong Liang1, et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics 2018; 8(16):4345-4358.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
    2018-10-20 海豹
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
    2018-08-03 kafei

    了解一下谢谢

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2049896, encodeId=479020498961e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sat Oct 20 19:45:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044998, encodeId=16642044998b6, content=<a href='/topic/show?id=a4d02358610' target=_blank style='color:#2F92EE;'>#乳头状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23586, encryptionId=a4d02358610, topicName=乳头状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu May 23 01:45:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738898, encodeId=7ce71e388984b, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Mar 05 06:45:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841280, encodeId=6f0f1841280bd, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jul 01 22:45:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363798, encodeId=9d611363e98a0, content=<a href='/topic/show?id=ba2c6984e3a' target=_blank style='color:#2F92EE;'>#甲状腺乳头状癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69847, encryptionId=ba2c6984e3a, topicName=甲状腺乳头状癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 07:45:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335962, encodeId=ff1f335962f8, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Aug 03 08:22:22 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335912, encodeId=fc5d33591267, content=学习了学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 03 06:42:25 CST 2018, time=2018-08-03, status=1, ipAttribution=)]
    2018-08-03 phoebeyan520

    学习了学习了,谢谢分享

    0